Bristol-Myers, AbbVie eye new use for myeloma drug Empliciti after phase 2 combo win

Bristol-Myers Squibb and AbbVie’s Empliciti hasn’t picked up an indication since its initial multiple myeloma approval back in 2015. But with impressive new survival data in hand, the partners could be on their way to changing that.